Hospital-at-Home Equipment Market Size to Hit USD 82.90 Billion by 2035 at a CAGR of 12.36%

The U.S. hospital-at-home equipment market is projected to reach $26.87 billion by 2035, while the European market is forecast to reach $21.28 billion. Growth is expected to be supported by a CMS waiver extension, adoption of wearable biosensors, and AI-enabled command centers, signaling a favorable long-term outlook for remote-care equipment providers.

Analysis

The investable variable is not the projected equipment market size; it is whether reimbursement permanence converts hospital-at-home from a pilot-capex category into a recurring care-delivery model. Hospitals will prioritize vendors that lower staffed-bed utilization, readmissions, and clinician labor per episode, favoring integrated monitoring/workflow platforms over stand-alone devices. This creates potential share pressure on commodity hardware suppliers, while GE HealthCare (GEHC), Philips (PHG), Medtronic (MDT), ResMed (RMD), and Masimo (MASI) have more credible routes to attach software, monitoring consumables, or service revenue to deployments.

Near-term equity impact is likely limited because hospital procurement cycles are 6-18 months and provider budgets remain constrained. The key second-order risk is that broader adoption shifts attractive acute episodes out of facilities but does not expand total reimbursement; in that case, hospitals capture most savings and technology vendors face price pressure. AI-command-center claims should be discounted until vendors disclose independently measurable reductions in length of stay, emergency-department boarding, readmissions, or labor hours per episode.

Consensus may overestimate the benefit to pure-play virtual-care equities such as Amwell (AMWL) and Teladoc (TDOC). Hardware and workflow adoption does not necessarily translate into profitable platform economics, particularly where hospitals retain patient ownership and negotiate software contracts as low-margin operating expenses. A durable re-rating requires a verified reimbursement framework plus disclosed multi-year contracts and improving gross-margin/retention metrics, not broad market-growth forecasts.

Key Decisions for Investors

• No immediate directional trade on the release; treat it as a 1-3 month regulatory and procurement watch item. Confirm the exact CMS waiver duration, eligible episode types, and reimbursement parity before underwriting revenue sensitivity for GEHC, PHG, MDT, RMD, or MASI.
• Build a watchlist long GEHC versus short AMWL only after evidence of enterprise contract wins or guidance commentary tying remote-care deployments to recurring software/service revenue. The pair expresses integrated-incumbent advantage while limiting broad healthcare-beta exposure; invalidate if AMWL reports material multi-year contracted revenue growth with expanding gross margin.
• Monitor MASI and RMD for hospital-at-home attach-rate disclosure over the next 2-4 earnings cycles. Consider longs only if management quantifies recurring sensor/consumable revenue and hospital demand without material price concessions; otherwise the category remains too small to affect estimates.
• For TDOC and AMWL, avoid treating regulatory optimism as a catalyst absent improved cash burn, retention, and enterprise bookings. A reimbursement extension can increase competition from hospital-owned programs and established device vendors rather than improve pure-play virtual-care economics.